Discrete Particles In Supporting Matrix Patents (Class 424/469)
-
Patent number: 6136344Abstract: An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antibacterial compounds in a fixed formulation. The fixed formulation is intended for oral use and in the form of an enteric coating layered tablet, an capsule or a multiple unit tableted dosage form. The multiple unit dosage form is most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with Helicobacter infections.Type: GrantFiled: April 15, 1996Date of Patent: October 24, 2000Assignee: Astra AktiebolagInventors: Helene Depui, Adam Rosinski
-
Patent number: 6132771Abstract: An oral pharmaceutical dosage form comprising a proton pump inhibitor and one or more prokinetic agents in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of multilayered tablets, capsules or multiple unit tableted dosage forms. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with gastro oesophageal reflux diseases.Type: GrantFiled: February 13, 1997Date of Patent: October 17, 2000Assignee: AstraZeneca ABInventors: Helene Depui, Agneta Hallgren
-
Patent number: 6120803Abstract: The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix is surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.Type: GrantFiled: August 10, 1998Date of Patent: September 19, 2000Assignee: ALZA CorporationInventors: Patrick S. L. Wong, Liang-Chang Dong, David E. Edgren, Felix Theeuwes, Phyllis I. Gardner, Francisco Jao, Jason J. Wan
-
Patent number: 6117450Abstract: The method of making a solid drug with controlled effective ingredient delivery for oral administration includes selecting a predetermined number of at least three of four compressed compositions containing an effective ingredient or effective ingredient combination defined by their release profile of effective ingredient and/or effective ingredient combination. The solid drug or medicinal preparation is formed according to known methods requiring only comparatively small apparatus expense and minimal time. Perorally administered solid drugs are made by this process which can provide widely varying pharmaceutically-required release profiles of effective ingredients or effective ingredient combinations, for example delayed release, uniformly maintained release or pulsatile release adjusted to fit a special rhythm.Type: GrantFiled: April 24, 1998Date of Patent: September 12, 2000Assignee: JENAPHARM GmbH & Co. KGInventors: Michael Dittgen, Sabine Fricke, Carsten Timpe, Hagen Gerecke, Annette Eichardt
-
Patent number: 6117453Abstract: A solid composition is disclosed comprising an active ingredient that is not in amorphous form in association with polyethylene oxide and conventional additives, excluding basic compounds. Such compositions are suitable for use as pharmaceutical compositions. A method for their preparation is also disclosed.Type: GrantFiled: October 14, 1997Date of Patent: September 12, 2000Assignee: Pharma PassInventors: Pawan Seth, Andre Stamm
-
Patent number: 6117452Abstract: The thermoforming of compositions containing active agents is carried out by processing compositions containing certain fatty esters in combination.Type: GrantFiled: August 12, 1998Date of Patent: September 12, 2000Assignee: Fuisz Technologies Ltd.Inventors: Nils Ahlgren, Joseph Cascone, Joan Fitzpatrick, Steven E. Frisbee, John Getz, Mark R. Herman, Bernard M. Kiernan, Barbara Montwill, Ed O'Donnell, Desiree Pereira, Pradeepkumar P. Sanghvi
-
Patent number: 6110500Abstract: A tablet for the controlled release of an active pharmaceutical ingredient. The tablet comprises a core having a donut-like configuration with a cylindrical hole extending through the center of the core. The core of the body comprises at least one active pharmaceutical agent and at least one hydrophilic, water-soluble, polymeric carrier. The core is coated with a hydrophobic, water-insoluble material covering all of the core except that which is defined by the cylindrical hole. Also included is a method of preparing a tablet for the controlled release of an active ingredient. The method comprises the steps of blending an active pharmaceutical ingredient, a water-soluble hydrophilic, polymeric carrier, and optionally an excipient, to form a mix; compressing the mix; punching a tablet from the mix; coating the tablet in a water insoluble, hydrophobic coating, then drilling a hole through the coated tablet.Type: GrantFiled: March 25, 1998Date of Patent: August 29, 2000Assignee: Temple UniversityInventor: Cherng-ju Kim
-
Patent number: 6103264Abstract: A process for preparing a controlled release composition with a controlled release matrix and containing a pharmaceutically active ingredient, which comprises granulating the active ingredient with a molten matrix material or with a matrix material while it is being melted and with optional additional inactive materials at a first elevated temperature, then cooling and screening the granulate, forming a fluidized bed of the resulting material at a second elevated temperature, and recovering the resulting product; and the product formed by the process.Type: GrantFiled: July 7, 1998Date of Patent: August 15, 2000Assignee: Arzneimittelwerk Dresden GmbHInventors: Torsten Hoffmann, Klaus Liebold, Joachim Wolf, Heiko Schumacher
-
Patent number: 6103263Abstract: The invention provides a delayed-pulse controlled release pharmaceutical tablet having:(a) from 20 to 60 wt. % of a low molecular weight hydroxypropyl cellulose having a number average molecular weight of 70,000 to 90,000;(b) from 4 to 10 wt. % of a high molecular weight hydroxypropyl cellulose having a number average molecular weight of 1,100,000 to 1,200,000;(c) a pharmacologically acceptable amount of a medicament; and(d) an inert solid diluent.Type: GrantFiled: November 17, 1994Date of Patent: August 15, 2000Assignee: Andrx Pharmaceuticals, Inc.Inventors: Der-Yang Lee, Chih-Ming Chen
-
Patent number: 6099859Abstract: A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.Type: GrantFiled: March 20, 1998Date of Patent: August 8, 2000Assignee: Andrx Pharmaceuticals, Inc.Inventors: Xiu Xiu Cheng, Chih-Ming Chen, Steve Jan, Joseph Chou
-
Patent number: 6096339Abstract: The invention disclosed pertains to a dosage form comprising an agent formulation comprising drug and pharmaceutical carrier of cooperating particle size and means for dispensing the agent formulation from the dosage form.Type: GrantFiled: April 4, 1997Date of Patent: August 1, 2000Assignee: ALZA CorporationInventors: Atul D. Ayer, Andrew Lam, Judy A. Magruder, Lawrence G. Hamel, Patrick S. L. Wong
-
Patent number: 6093420Abstract: Sustained release dosage forms of high dose insoluble drugs such as ibuprofen and methods for their manufacture are disclosed.Type: GrantFiled: July 8, 1997Date of Patent: July 25, 2000Assignee: Edward Mendell Co., Inc.Inventor: Anand R. Baichwal
-
Patent number: 6083532Abstract: Depot drug formulations include the pharmaceutical itself and a three component release rate controlling matrix composition. The three components of the matrix composition are (1) a pH dependent gelling polymer such as an alginate component, (2) an enteric polymer component, such as Eudragit.RTM. L or S, and (3) a pH independent gelling polymer, such as hydroxy propyl methyl cellulose or polyethylene oxide. The drug release rate can be adjusted by changing the amount of one or more of these components of the composition.Type: GrantFiled: December 5, 1997Date of Patent: July 4, 2000Assignee: Duramed Pharmaceuticals, Inc.Inventors: Guohua Zhang, Prasad Pinnamaraju, Muhammad Ali
-
Patent number: 6083533Abstract: A layered tablet for the controlled release of active substances in a liquid medium comprising at least one active substance-containing, layered matrix with contact surfaces to the liquid medium which are at least partially provided with a cover layer delaying or preventing the active substance release, is characterized by the fact that the cover layer is at least one additional layer lying with thickness gradients on contact surfaces of the layered, prefabricated matrix, or that the matrix is at least one additional layer lying with thickness gradients on contact surfaces of the layered, prefabricated cover layer, which additional layer is applied by pressing powdery or granular material on the layered, prefabricated matrix or on the layered, prefabricated cover layer.Type: GrantFiled: January 7, 1998Date of Patent: July 4, 2000Assignee: LTS Lohmann Therapie-Systeme GmbHInventor: Karsten Cremer
-
Patent number: 6080428Abstract: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally", that is in the evening or at night.Type: GrantFiled: January 14, 1995Date of Patent: June 27, 2000Inventor: David J. Bova
-
Patent number: 6077539Abstract: This invention comprises a non-vasoactive, supra-vasoactive syndrome ("SVS") minimized dosage form for treatment of migraine in a human comprising (i) rapid availability metoclopramide in at least about an effective local gastrointestinal amount; (ii) at least one long acting NSAID such as naproxen sodium in a therapeutically effective amount; (iii) wherein said dosage form is a coordinated dosage form; and, (iv) wherein the dosage form is absent 5HT agonist vasoactive agents, and preparation thereof. Acid-base stable dosage forms are noted. This invention further comprises methods of migraine treatment, and methods for rapid introduction of oral NSAID into the small bowel.Type: GrantFiled: November 10, 1997Date of Patent: June 20, 2000Assignee: Pozen, Inc.Inventors: John R. Plachetka, Zakauddin T. Chowhan
-
Patent number: 6074669Abstract: A pharmaceutical composition in the form of a tablet or a capsule for the controlled release of diltiazem, comprises about 30 to about 97% by weight of a hydrophilic polymer, about 0.5 to about 30% by weight of an enteric (pH-dependent) polymer, and about 2.5 to about 60% by weight of diltiazem or a pharmaceutically acceptable salt or ester thereof. The ratio of hydrophilic polymer to enteric polymer is in the range of about 1:1 to about 15:1. Such a pharmaceutical composition releases diltiazem at a rate that allows effective plasma levels of diltiazem to be maintained over a period of twenty-four hours after administration to human adult subjects.Type: GrantFiled: December 4, 1997Date of Patent: June 13, 2000Assignee: Ranbaxy Laboratories LimitedInventors: Vishnubhotla Nagaprasad, Himadri Sen
-
Patent number: 6074670Abstract: The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a size less than 20 .mu.m, a hydrophilic polymer and, optionally, a surfactant, the polymer making up at least 20% by weight of (a); and (b) optionally one or several outer phase(s) or layers(s). The invention also provides a method for preparing said composition.Type: GrantFiled: January 9, 1998Date of Patent: June 13, 2000Assignee: Laboratoires Fournier, S.A.Inventors: Andre Stamm, Pawan Seth
-
Patent number: 6068854Abstract: A peroral depot medicament with controlled active substance release is composed of a gelatine matrix that continuously dissolves in an aqueous medium above 37.degree. C., and a medicament distributed therein. The release of the medicament, that may be easily or scarcely soluble, lipophilic or hydrophilic, is variable in time and may be adjusted according to the medicament.Type: GrantFiled: December 12, 1996Date of Patent: May 30, 2000Assignee: Alfatec-Pharma GmbHInventors: Jens-Christian Wunderlich, Ursula Schick, Jurgen Werry, Jurgen Freidenreich
-
Patent number: 6068855Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.Type: GrantFiled: August 18, 1997Date of Patent: May 30, 2000Assignee: Euro-Celtique S. A.Inventors: Stewart Thomas Leslie, Trevor John Knott, Hasssan Mohammad, Derek Allan Prater
-
Patent number: 6066339Abstract: An oral morphine multiparticulate formulation for once-daily administration to a patient, comprising sustained release particles each having a core containing water soluble morphine and an osmotic agent, the core being coated with a rate-controlling polymer coat comprised of ammonio methacrylate copolymers in an amount sufficient to achieve therapeutically effective plasma levels of morphine over at least 24 hours in the patient.Type: GrantFiled: November 25, 1997Date of Patent: May 23, 2000Assignee: Elan Corporation, plcInventors: Paul Stark, Sean Cunningham, Jagathesan Moodley
-
Patent number: 6056949Abstract: The present invention relates to a process for the preparation of spherical or substantially spherical, practically dust-free aromatic and odoriferous granulated material which is free-flowing, mechanically stable and has a narrow grain-size distribution.Type: GrantFiled: April 6, 1998Date of Patent: May 2, 2000Assignee: Givaudan Roure (International) SAInventors: Heini Menzi, Matthias Perren, Rudolf Ringgenberg
-
Patent number: 6054145Abstract: Disclosed is a process for the preparation of pharmaceutical dosage units containing as an active substance of from 0.005 to 1.0% by weight of micronised Org 30659, comprising (a) a mixing step comprising bringing into association the active substance and a suitable carrier to form a mixture, and (b) a granulating step in which the mixture is granulated to form agglomerates or granules by wetting the mixture with a binder liquid, the wetting being conducted under agitation, characterised in that the granulation step (b) is conducted so as to exert on the granules a shear force which does not exceed the tensile strength of the agglomerates or granules. The process leads to granules and tablets having an excellent content/uniformity.Type: GrantFiled: March 12, 1999Date of Patent: April 25, 2000Assignee: Akzo Nobel, N.V.Inventors: Herman Vromans, Hendrika Gerardina Maria Poels-Janssen
-
Patent number: 6033685Abstract: The present invention provides a tablet for the controlled release of an active agent comprising (a) a matrix layer comprising an active agent embedded in a non-swelling, non-gelling hydrophobic matrix; (b) a first barrier layer laminated to a single face of the matrix layer; and (c) an optional second barrier layer laminated to the opposite face of the matrix layer and oppositely disposed to the first barrier layer; wherein the matrix comprises up to about 80% active agent and from about 5% to about 80% by weight of nonswellable waxes or polymeric material insoluble in aqueous medium, and the first and second barrier layers independently comprise (1) polymeric material exhibiting a high degree of swelling and gelling in aqueous medium or (2) nonswellable wax or polymeric material insoluble in aqueous medium.Type: GrantFiled: June 29, 1998Date of Patent: March 7, 2000Assignee: Abbott LaboratoriesInventors: Yihong Qiu, Jay S. Trivedi, Sharon L. Graham, Kolette M. Flood, Steven L. Krill
-
Patent number: 6024981Abstract: The invention is directed to a hard tablet that can be stored, packaged and processed in bulk. Yet the tablet dissolves rapidly in the mouth of the patient with a minimum of grit. The tablet is created from an active ingredient mixed into a matrix of a non-direct compression filler and a relatively high lubricant content.Type: GrantFiled: April 9, 1998Date of Patent: February 15, 2000Assignee: Cima Labs Inc.Inventors: Rajendra K. Khankari, John Hontz, Sara J. Chastain, Leo Katzner
-
Patent number: 6013281Abstract: A new oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutical excipients having a water soluble separating layer and an enteric coating layer. The core material as such is alkaline reacting and the separating layer between the alkaline reacting core material and the enteric coating layer is formed in situ as a water soluble salt between the alkaline reacting compound(s) and the enteric coating polymer. The invention also describes a new efficient process for the manufacture of such a dosage form comprising two functionally different layers in one manufacturing step, and its use in medicine.Type: GrantFiled: March 8, 1996Date of Patent: January 11, 2000Assignee: Astra AktiebolagInventors: Per Johan Lundberg, Kurt Lovgren
-
Patent number: 5998431Abstract: A sustained-release matrix for dental application includes either an anti-microbial agent or a colorant that is released from the matrix when the matrix contacts water. The preferred matrices include a water-soluble polymer and a water-insoluble support resin.Type: GrantFiled: April 16, 1998Date of Patent: December 7, 1999Assignee: Gillette Canada Inc.Inventors: Mingchih M. Tseng, Carl M. Philbrook
-
Patent number: 5980942Abstract: A zero-order sustained-release delivery system for delivery of carbamazepine. A matrix tablet formulations of carbamazepine comprising hydrophilic polymer gel which inhibits transformation of carbamazepine into carbamazepine dihydrate by causing morphologic changes of carbamazepine crystals and results in amorphous form of carbamazepine present in the polymer matrix.Type: GrantFiled: January 23, 1998Date of Patent: November 9, 1999Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Ifat Katzhendler, Michael Friedman
-
Patent number: 5976570Abstract: A process for making pharmaceutical dosage units containing a therapeutic quantity of one or more low dosage medicinal agent comprising granulating said medicinal agent in an aqueous medium which contains a pharmaceutically acceptable surfactant agent and, optionally, further processing the product of said granulating into a tablet or capsule dosage unit.Type: GrantFiled: July 15, 1996Date of Patent: November 2, 1999Assignee: Applied Analytical Industries, Inc.Inventors: Frank C. Greaves, James Swarbrick, Martin W. Beasley, Andrew W. Suddith, Henry C. Caldwell
-
Patent number: 5965166Abstract: Direct compressed solid pharmaceutical dosage forms containing:a) from about 40 to about 95% by weight acetaminophen;b) from about 1 to about 60% by weight of a direct compression vehicle comprising microcrystalline cellulose; andc) from about 0.01 to about 4.0% by weight of a pharmaceutically-acceptable lubricant are disclosed. The acetaminophen and direct compression vehicle are combined under high shear conditions which are sufficient to transform acetaminophen and direct compression vehicle into a homogenous granulate without degradation. In preferred aspects of the invention, the lubricant is also combined with the acetaminophen and direct compression vehicle under high shear conditions. Methods of preparing the directly compressed solid pharmaceutical dosage forms and methods of treatment with the dosage forms are also disclosed. The methods are particularly well suited for preparing directly compressed dosage forms containing high load (i.e.Type: GrantFiled: November 5, 1997Date of Patent: October 12, 1999Assignee: Edward Mendell Co., Inc.Inventors: Edward A. Hunter, Joseph A. Zeleznik, Bob E. Sherwood
-
Patent number: 5965163Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.Type: GrantFiled: September 30, 1997Date of Patent: October 12, 1999Assignee: Euro-Celtique, S.A.Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Trevor John Knott, Joanne Heafield, Deborah Challis
-
Patent number: 5958458Abstract: A pharmaceutical multiple unit particulate formulation in the form of coated cores which includes a pharmaceutically acceptable carrier selected from calcium carbonate, calcium silicate, calcium magnesium silicate, calcium phosphate, kaolin, sodium hydrogen carbonate, sodium sulfate, barium carbonate, barium sulfate, magnesium sulfate, magnesium carbonate, and activated carbon, and an active substance in a layer on the outer surface of the cores.Type: GrantFiled: August 1, 1995Date of Patent: September 28, 1999Assignee: Dumex-Alpharma A/SInventors: Tomas Norling, Lone Norgaard Jensen, Jens Hansen
-
Patent number: 5942248Abstract: Non-steroidal anti-inflammatory drugs, such as indomethacin, and other pharmaceutically active compounds, are formulated with bile acids or their salts and conjugates. Bile acids previously proposed for use in such formulations have placed an unacceptable toxic load on the liver and/or cells of the gastrointestinal tract, causing abnormal liver function or cell erosion. In this invention, the bile acid is a low detergent bile acid, such as ursodeoxycholate. Stabilization of the bile acid pool results in enhanced and predictable enterohepatic recycling of NSAIDs (and other drugs) and a reduced risk of toxicity.Type: GrantFiled: February 2, 1995Date of Patent: August 24, 1999Assignee: Cortecs LimitedInventor: Stephen George Barnwell
-
Patent number: 5942244Abstract: A tablet for the local and slow release of herbal medication into the oral cavity of a subject. Also provided is a method of making the tablet and a method of using the tablet. The tablet includes a pharmaceutically effective amount of a herbal medication, a polymeric matrix material such as ethyl cellulose, a release enhancer such as PEG 4000 and a filler such as lactose. The tablet is characterized by long dissolution times of up to 120 minutes.Type: GrantFiled: July 31, 1997Date of Patent: August 24, 1999Assignee: Farmo-Nat Ltd.Inventors: Michael Friedman, Orna Levin, Yochanan Forman, Doron Friedman
-
Patent number: 5942242Abstract: A medicament for nasal administration to be used for disease prevention or treatment comprising a vaccine or a pharmacologically active peptide compounded with an ion exchange resin or adsorbent resin powder whose mean particle size is not larger than 200 .mu.m.Type: GrantFiled: July 10, 1996Date of Patent: August 24, 1999Assignee: LTT Institute Co., LtdInventors: Yutaka Mizushima, Yasuo Kosaka, Kayoko Hosokawa, Ryozo Nagata, Megumu Higaki, Rie Igarashi, Tetsuo Ebata
-
Patent number: 5928666Abstract: The present invention is directed to a stable crystalline form of estradiol suitable for incorporation into pharmaceutical formulations. The invention further provides methods of preparing said crystalline form of estradiol. The invention further provides pharmaceutical formulations comprising said crystalline form of estradiol. The invention further provides a method of treatment of an individual in need of such administration by the transdermal administration of estradiol from a polymeric matrix comprising the crystal structure of estradiol of the present invention.Type: GrantFiled: November 10, 1997Date of Patent: July 27, 1999Assignee: Cygnus Inc.Inventors: Kathleen C. Farinas, Yalia Jayalakshmi, Susanne M. Lee, Pravin L. Soni
-
Patent number: 5922356Abstract: The present invention relates to a sustained release formulation used for treatment or prevention of the diseases, which contains a therapeutically effective substance as an active ingredient, collagen as a drug carrier, and glycosaminoglycan as an additive. The formulation allows controlled release of the therapeutically effective substance.Type: GrantFiled: October 9, 1997Date of Patent: July 13, 1999Assignees: Sumitomo Pharmaceuticals Company, Limited, Koken Co., Ltd.Inventors: Norimasa Koseki, Akihiko Sano
-
Patent number: 5910322Abstract: Pharmaceutical formulations for oral administration, comprising a matrix which comprises a .beta.-lactam antibiotic optionally in combination with a .beta.-lactamase inhibitor, granules in a delayed release form dispersed within the matrix, which comprise a .beta.-lactam antibiotic optionally in combination with a .beta.-lactamase inhibitor, the overall tablet formulation including a .beta.-lactam antibiotic and a .beta.-lactamase inhibitor.Type: GrantFiled: October 2, 1997Date of Patent: June 8, 1999Assignee: SmithKline Beecham p.l.c.Inventors: Ernest Lionel Gilbert Rivett, Francis Walter Grimmett, Michael William Hartnell
-
Patent number: 5906833Abstract: A nutritional supplement contains plural parts. Each of the plural parts is chronologically appropriate for its scheduled time of consumption. The nutritional supplement is contained in a palatable base, for example, a food bar which masks any unpleasant taste or texture of the nutrient. The nutritional supplement may contain any one or several nutrients including drugs, vitamins, herbs, hormones, enzymes and/or other nutrients in chronologically appropriate dosages in each part or sub-part.Type: GrantFiled: May 22, 1995Date of Patent: May 25, 1999Inventor: Ronald M. Klatz
-
Patent number: 5900425Abstract: The invention relates to pharmaceutical preparations having controlled release of active compound and to processes for their preparation, in particular for poorly soluble active compounds having problematic bioavailability.Type: GrantFiled: September 19, 1997Date of Patent: May 4, 1999Assignee: Bayer AktiengesellschaftInventors: Venkata-Rangarao Kanikanti, Wolfgang Muck, Andreas Ohm, Peter Kurka, Gerd Toppel
-
Patent number: 5889028Abstract: A method is provided to treat inflammatory bowel disease by locally administering to the colon an effective amount of nicotine or a pharmaceutically acceptable salt thereof, preferably via formulations adapted for delayed oral release or rectal administration. Further provided is a novel formulation for the oral administration of nicotine comprising a polyacrylic polymer complexed with nicotine.Type: GrantFiled: August 7, 1997Date of Patent: March 30, 1999Assignee: Mayo Foundation for Medical Education and ResearchInventors: William Sandborn, John Rhodes, Peter Rhodes, Brian Kenneth Evans
-
Patent number: 5879714Abstract: A controlled-release pharmaceutical composition for oral administration comprising a multitude of granules made by dissolving or dispersing a drug and a water-insoluble polymer in a molten carrier, solidifying the resultant material, and grinding the resultant solid into granules.Type: GrantFiled: April 23, 1997Date of Patent: March 9, 1999Assignee: Bernard Charles ShermanInventor: Bernard Charles Sherman
-
Patent number: 5869097Abstract: An osmotic caplet is disclosed comprising an osmotic caplet exit for delivering a preselected dose of drug to a patient in need of therapy.Type: GrantFiled: November 2, 1992Date of Patent: February 9, 1999Assignee: Alza CorporationInventors: Patrick S.-L. Wong, Felix Theeuwes, George V. Guittard, Atul D. Ayer
-
Patent number: 5866169Abstract: This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate is used to reduce the risk or prevent or retard the development of cisplatin induced nephrotoxicity, myelosuppression, and neurotoxicity, and wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate potentiates the antitumor activity of cisplatin when treating human patients with cancer. This invention also teaches novel formulations containing 2,2'-dithio-bis-ethane sulfonate alone or in combination with cisplatin in lyophilized or dissolved in an aqueous formulations which can be administered to patients with cancer who are being treated with cisplatin.Type: GrantFiled: June 18, 1997Date of Patent: February 2, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick Herman Hausheer, Kochat Haridas, Dhanabalan Murali, Dasharatha Gauravaram Reddy, Seetharamulu Peddaiahgari
-
Patent number: 5866163Abstract: The present invention is a method of preparing rapidly dissolving comestible units such as tablets. The present invention also includes an apparatus for making the comestible units and the units themselves. The product prepared in accordance with the present invention can include active ingredients and is capable of dissolving in the mouth of the consumer within several seconds. The unit dosage forms prepared in accordance with the present invention are particularly useful as antacids and as a delivery vehicle for biologically active ingredients, especially those which are ideally combined with antacid ingredients in order to ameliorate the effects of antacid environment.Type: GrantFiled: December 19, 1996Date of Patent: February 2, 1999Assignee: Fuisz Technologies Ltd.Inventors: Garry L. Myers, Gerald E. Battist, Richard C. Fuisz
-
Patent number: 5853756Abstract: The present invention provides oral formulations of Ranitidine Hydrochloride in the form of coated tablets and capsules which produce controlled or regulated dissolution and release at a fairly uniform rate over long periods--as long as 12 to 24 hours--to maintain Ranitidine at desired levels above the MEC.Type: GrantFiled: September 1, 1995Date of Patent: December 29, 1998Assignee: J. B. Chemicals & Pharmaceuticals LimitedInventors: Shri Shirish Bhagwanlal Mody, Madhukant Mansukhlal Doshi, Milind Dattatraya Joshi
-
Patent number: 5853762Abstract: The present invention is a method and a dosage unit for delivery of a controlled-release system. The dosage unit is a quick dissolve unit which can be prepared by mixing uncured shearform matrix and a controlled-release system, either molding or compacting a unit dosage form and curing the shearform matrix. The controlled-release systems used in the present invention include instantaneous release components, delayed release components, sustained release components, and combinations thereof.Type: GrantFiled: August 16, 1996Date of Patent: December 29, 1998Assignee: Fuisz Technologies LtdInventors: Garry L. Myers, Gerald E. Battist, Richard C. Fuisz
-
Patent number: 5849327Abstract: Diseases of the colon are treated by oral ingestion of a unit dosage form containing a plurality of porous microscopic beads, the pores containing an active agent or drug and plugged with a polysaccharide that is chemically degradable by colon-specific bacteria. The dosage form further contains a coating of an enteric material that remains intact until the dosage form reaches the colon.Type: GrantFiled: September 27, 1996Date of Patent: December 15, 1998Assignee: Advanced Polymer Systems, Inc.Inventors: David L. Berliner, Sergio Nacht
-
Patent number: 5849329Abstract: A process is described for preparing pharmaceutical compositions by co-grinding or dry mixing the active substance with cyclodextrins or with hydrophilic polymer materials which swell on contact with water. Homogeneous compositions are obtained from which the active substance is released very rapidly into an aqueous medium.Type: GrantFiled: September 7, 1995Date of Patent: December 15, 1998Assignee: Jagotec AGInventors: Ubaldo Conte, Aldo La Manna, Paolo Giunchedi
-
Patent number: 5843925Abstract: The invention relates to a method for inhibiting angiogenesis and proliferation of endothelial cells by administering an inhibitory amount of a 7-?substituted amino!-9-?(substituted glycyl)amido!-6-demethyl-6-deoxytetracycline of Formula I: ##STR1## wherein R, R.sub.2, R.sub.3, and W are as defined in the specification. The invention also relates to a method for inhibiting proliferation of tumor cells and tumor growth by administering an inhibitory amount of a compound of Formula I in combination with a chemotherapeutic agent or radiation therapy. The invention also relates to compositions containing an effective inhibitory amount of a compound of Formula I in a pharmaceutically acceptable carrier.Type: GrantFiled: December 13, 1994Date of Patent: December 1, 1998Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Peter Bohlen